{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:15:34Z","timestamp":1766729734858,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"DOI":"10.7759\/cureus.100095","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:11:08Z","timestamp":1766729468000},"source":"Crossref","is-referenced-by-count":0,"title":["Allergic Reactions to Brimonidine 0.15%: A Case Series"],"prefix":"10.7759","author":[{"given":"Fatin Nabila","family":"Mat Nawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mae-Lynn C","family":"Bastion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50226.x","article-title":"New glaucoma medications in the geriatric population: efficacy and safety","volume":"50","author":"Novack GD","year":"2002","unstructured":"Novack GD, O'Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002, 50:956-62. 10.1046\/j.1532-5415.2002.50226.x","journal-title":"J Am Geriatr Soc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(98)91048-x","article-title":"Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension","volume":"105","author":"LeBlanc RP","year":"1998","unstructured":"LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology. 1998, 105:1960-7. 10.1016\/s0161-6420(98)91048-x","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(98)00286-4","article-title":"Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients","volume":"127","author":"Katz LJ","year":"1999","unstructured":"Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol. 1999, 127:20-6. 10.1016\/s0002-9394(98)00286-4","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100030047020","article-title":"Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions","volume":"113","author":"Butler P","year":"1995","unstructured":"Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995, 113:293-6. 10.1001\/archopht.1995.01100030047020","journal-title":"Arch Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026724","article-title":"Brimonidine related acute follicular conjunctivitis: onset time and clinical presentations, a long-term follow-up","volume":"100","author":"Yeh PH","year":"2021","unstructured":"Yeh PH, Cheng YC, Shie SS, et al.. Brimonidine related acute follicular conjunctivitis: onset time and clinical presentations, a long-term follow-up. Medicine (Baltimore). 2021, 100:10.1097\/MD.0000000000026724","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(02)80094-1","article-title":"Allergic reactions to brimonidine in patients treated for glaucoma","volume":"37","author":"Blondeau P","year":"2002","unstructured":"Blondeau P, Rousseau JA. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002, 37:21-6. 10.1016\/S0008-4182(02)80094-1","journal-title":"Can J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200006000-00006","article-title":"Incidence of brimonidine allergy in patients previously allergic to apraclonidine","volume":"9","author":"Williams GC","year":"2000","unstructured":"Williams GC, Orengo-Nania S, Gross RL. Incidence of brimonidine allergy in patients previously allergic to apraclonidine. J Glaucoma. 2000, 9:235-8. 10.1097\/00061198-200006000-00006","journal-title":"J Glaucoma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(96)82029-7","article-title":"Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension","volume":"41","author":"Schuman JS","year":"1996","unstructured":"Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996, 41:27-37. 10.1016\/s0039-6257(96)82029-7","journal-title":"Surv Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200404000-00014","article-title":"Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy","volume":"13","author":"Manni G","year":"2004","unstructured":"Manni G, Centofanti M, Sacchetti M, Oddone F, Bonini S, Parravano M, Bucci MG. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma. 2004, 13:163-7. 10.1097\/00061198-200404000-00014","journal-title":"J Glaucoma"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1038\/sj\/eye\/6700053","article-title":"Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure","volume":"16","author":"Watts P","year":"2002","unstructured":"Watts P, Hawksworth N. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure. Eye (Lond). 2002, 16:132-5.","journal-title":"Eye (Lond)"},{"key":"ref11","unstructured":"Alphagan (brimonidine tartrate ophthalmic solution 0.2%) prescribing information. (2016). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020613s031lbl.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1076\/0271-3683(200002)20:2;1-d;ft085","article-title":"Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells","volume":"20","author":"Jean M","year":"2000","unstructured":"Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000, 20:85-94. 10.1076\/0271-3683(200002)20:2;1-d;ft085","journal-title":"Curr Eye Res"},{"key":"ref13","article-title":"Assessment of the comfort and tolerance of 0.5% carboxymethylcellulose preserved with purite (refresh tears) in dry eye sufferers","volume":"39","author":"Rozen S","year":"1998","unstructured":"Rozen S, Abelson M, Giovanoni A, Welch D. Assessment of the comfort and tolerance of 0.5% carboxymethylcellulose preserved with purite (refresh tears) in dry eye sufferers. Invest Ophthalmol Vis Sci. 1998, 39:","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200204000-00007","article-title":"Twelve-month evaluation of brimonidine-Purite versus brimonidine in patients with glaucoma or ocular hypertension","volume":"11","author":"Katz LJ","year":"2002","unstructured":"Katz LJ. Twelve-month evaluation of brimonidine-Purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002, 11:119-26. 10.1097\/00061198-200204000-00007","journal-title":"J Glaucoma"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/108076803762718097","article-title":"A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension","volume":"19","author":"Mundorf T","year":"2003","unstructured":"Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003, 19:37-44. 10.1089\/108076803762718097","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(98)00450-4","article-title":"Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy","volume":"127","author":"Shin DH","year":"1999","unstructured":"Shin DH, Glover BK, Cha SC, Kim YY, Kim C, Nguyen KD. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. Am J Ophthalmol. 1999, 127:511-5. 10.1016\/s0002-9394(98)00450-4","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2005.21.337","article-title":"Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension","volume":"21","author":"Craven ER","year":"2005","unstructured":"Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005, 21:337-48. 10.1089\/jop.2005.21.337","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.9.1230","article-title":"Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial","volume":"124","author":"Sherwood MB","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006, 124:1230-8. 10.1001\/archopht.124.9.1230","journal-title":"Arch Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802333167","article-title":"Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy","volume":"24","author":"Motolko MA","year":"2008","unstructured":"Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008, 24:2663-7. 10.1185\/03007990802333167","journal-title":"Curr Med Res Opin"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850299","article-title":"Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension","volume":"18","author":"Gandolfi S","year":"2001","unstructured":"Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001, 18:110-21. 10.1007\/BF02850299","journal-title":"Adv Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/438908-allergic-reactions-to-brimonidine-015-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T06:11:09Z","timestamp":1766729469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/438908-allergic-reactions-to-brimonidine-015-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100095","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,25]]}}}